logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11230541 B1

PDFFull Text
Date of Patent:
Jan. 25, 2022

Filed:

Jul. 26, 2018

Heterocyclic compound

Applicant:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Inventors:

Eiji Kimura, Kanagawa, JP;

Masaki Ogino, Kanagawa, JP;

Yasuhisa Kohara, Kanagawa, JP;

Tomoko Ohashi, Kanagawa, JP;

Tomohiro Kaku, Kanagawa, JP;

Yuya Oguro, Kanagawa, JP;

Shigemitsu Matsumoto, Kanagawa, JP;

Takeshi Wakabayashi, Kanagawa, JP;

Norihito Tokunaga, Kanagawa, JP;

Taku Kamei, Kanagawa, JP;

Mitsuhiro Ito, Kanagawa, JP;

Assignee:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Attorney:

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Primary Examiner:

Shawquia Jackson

Int. Cl.
CPC ...
C07D 409/12 (2006.01); C07D 401/12 (2006.01); C07D 249/18 (2006.01); A61P 25/28 (2006.01); A61P 25/24 (2006.01); A61P 25/06 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); C07D 231/56 (2006.01); C07D 235/06 (2006.01);
U.S. Cl.
CPC ...
C07D 409/12 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2095 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61P 25/06 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); C07D 231/56 (2013.01); C07D 235/06 (2013.01); C07D 249/18 (2013.01); C07D 401/12 (2013.01);
Abstract

Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Find Patent Forward Citations

Loading…